Skip to content
ZR-75-30
Tissue
乳房、乳腺
Disease
無特定類型的侵襲性乳腺癌
Metastatic site
腹水
Synonyms
ZR75-30, ZR7530

Documents

ZR-75-30

Cell line · Product number 305389

ZR-75-30 is a human breast cancer cell line derived from a ductal carcinoma. Genomic profiling studies have shown that ZR-75-30 harbors amplification of t...

US$550.00excl. tax and shipping
Low stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

ZR-75-30 是一種源自導管癌的人類乳癌細胞系。 基因組分析研究顯示,ZR-75-30 攜帶 ERBB2/HER2 基因的擴增,該基因是部分乳癌亞型中的關鍵驅動因子。此擴增導致 HER2 蛋白質表達增加,而這已被證實與細胞增殖加速及對特定療法的抗藥性有關。 此外,ZR-75-30 在表皮生長因子受體(EGFR)訊號傳導路徑上呈現變異,包括 EGFR 相關基因的增益,這表明該細胞系可能有助於研究 HER2 靶向治療及其抗藥性機制。

轉錄組分析將 ZR-75-30 歸類為乳腺癌的管腔亞型,這支持了其用於研究內分泌治療反應的相關性。 該細胞系已被納入評估精準醫學方法的研究中,其中分子特徵分析有助於預測針對性治療的反應。鑑於其分子特徵,ZR-75-30 廣泛用作評估激素受體靶向療法和 HER2 抑制劑的臨床前模型,使其成為乳癌研究中極具價值的工具。

Tissue
乳房、乳腺
Disease
無特定類型的侵襲性乳腺癌
Metastatic site
腹水
Synonyms
  • ZR75-30
  • ZR7530

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
Biosafety level
1

03Characteristics

Morphology
上皮性
Cell type
上皮性
Doubling time
110 小時

04Identifiers

Citation
ZR-75-30(Cytion 型號 305389)
NCBI TaxID
9606
Cellosaurus
CVCL_1661

05Expression and susceptibility

Mutational profile
突變:基因融合,APPBP2 + HGNC、PHF20L1,名稱=APPBP2-PHF20L1。基因融合,BCAS3 + HGNC、HOXB9,名稱=BCAS3-HOXB9。 基因融合,COL14A1 + HGNC,SKAP1,名稱=COL14A1-SKAP1。基因融合,DDX5 + HGNC,DEPTOR,名稱=DDX5-DEPTOR。 基因融合,BCAS3 + HGNC,ERBB2,名稱=ERBB2-BCAS3。基因融合,ENPP2 + HGNC,PLEC,名稱=PLEC-ENPP2、PLEC1-ENPP2。 基因融合,PCGF2 + HGNC,TAOK1,名稱=TAOK1-PCGF2。基因融合,NRIP1 + HGNC,TIAM1,名稱=TIAM1-NRIP1。 基因融合,ARHGAP32 + HGNC,TIMM23,名稱=TIMM23-ARHGAP32。基因融合,LASP1 + HGNC,TRPS1,名稱=TRPS1-LASP1。 基因融合,CWC25 + HGNC,USP32,名稱=USP32-CWC25、USP32-CCDC49。基因融合,OPRD1 + HGNC,ZMYM4,名稱=ZMYM4-OPRD1。 突變,BRAF,單一突變,p.Ile326Thr (c.977T>C),雜合子;CDH1,單一突變,p.Glu243Ter (c.727G>T),純合子。

06Handling and culture

Culture medium
RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 10% FBS 及 10 µg/ml 胰島素
Fluid renewal
每週 2 至 3 次
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。

為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Donor age
47年
Ethnicity
非裔美國人